Form 4: Revolution Medicines CEO Exercises Options and Sells Shares Under 10b5-1 Plan

Mark A. Goldsmith, CEO of Revolution Medicines, executed stock options and sold 30,000 shares of common stock at an average price of $50.3591 per share on October 11, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On October 11, 2024, Mark A. Goldsmith, the CEO of Revolution Medicines, exercised stock options to acquire 30,000 shares of common stock at a price of $4.09 per share.
• Simultaneously, Goldsmith sold 30,000 shares of common stock at an average price of $50.3591 per share.
• These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on December 1, 2023.
• Following these transactions, Goldsmith directly owns 300,170 shares of Revolution Medicines common stock.
• Goldsmith also has indirect ownership through several trusts: Jonathan Goldsmith Revocable Trust (25,424 shares), Rebecca Eve Goldsmith Trust (25,424 shares), and Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust (465,604 shares).
• The reported transactions also include 188,750 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction under a pre-existing plan. The sale price is significantly higher than the exercise price, which could be viewed positively, but it's not necessarily indicative of a major shift in sentiment.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to use 10b5-1 plans to diversify their holdings and avoid accusations of trading on inside information. The sale price suggests continued investor confidence in Revolution Medicines.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their stock holdings in a compliant manner.
• Comparable companies in the biotechnology sector, such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals, also see regular filings of Form 4 documents related to insider trading activities.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders as they are part of a pre-planned trading strategy.
• Shareholders may view the transactions as a routine part of executive compensation and portfolio management.

Key Dates